ABCL Graph | AbCellera Biologics Inc.

ABCL Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

2026-06-30: Revenue $4.05M; Research and development $45.99M; Selling, general and administrative $13.85M; Operating expenses $66.83M.
2026-03-31: Revenue $8.31M; Research and development $46.66M; Selling, general and administrative $12.33M; Operating expenses $65.83M.
2025-12-31: Revenue $44.85M*; Research and development $50.09M*; Selling, general and administrative (m); Operating expenses $73.44M*.
2025-09-30: Revenue $8.96M; Research and development $55.03M; Selling, general and administrative (m); Operating expenses $85.23M.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period end	Revenue	Research and development	Selling, general and administrative	Operating expenses	Income tax	Net income
2026-06-30	$4.05M	$45.99M	$13.85M	$66.83M	-$3.54M	-$55.43M
2026-03-31	$8.31M	$46.66M	$12.33M	$65.83M	-$6.37M	-$43.16M
2025-12-31	$44.85M*	$50.09M*	(m)	$73.44M*	-$10.55M*	-$8.95M*
2025-09-30	$8.96M	$55.03M	(m)	$85.23M	-$11.65M	-$57.12M
2025-06-30	$17.08M	$39.21M	$21.99M	$66.67M	-$1.62M	-$34.73M
2025-03-31	$4.24M	$42.50M	$19.07M	$66.89M	-$7.36M	-$45.62M
2024-09-30	$6.51M	$40.97M	(m)	$100.17M	-$11.53M	-$51.11M
2024-06-30	$7.32M	$40.93M	(m)	$100.78M	-$11.26M	-$36.93M
2024-03-31	$9.95M	$39.29M	(m)	$64.85M	-$2.14M	-$40.61M
2023-09-30	$6.60M	$37.92M	(m)	$61.49M	-$10.67M	-$28.61M
2023-06-30	$10.06M	$36.47M	(m)	$61.45M	-$7.48M	-$30.53M
2023-03-31	$12.19M	$52.65M	(m)	$77.07M	-$8.04M	-$40.11M
2022-09-30	$101.38M	$26.58M	(m)	$63.65M	$19.96M	$26.62M
2022-06-30	$45.92M	$26.68M	(m)	$54.31M	-$101.00K	-$6.79M
2022-03-31	$316.58M	$26.37M	(m)	$91.63M	$62.24M	$168.57M
2021-09-30	$5.51M	$17.45M	(m)	$33.60M	-$3.59M	-$21.38M
2021-06-30	$27.64M	$15.05M	(m)	$34.68M	$250.00K	-$2.32M
2021-03-31	$202.74M	$12.35M	(m)	$44.67M	$44.27M	$117.22M
2020-09-30	$9.36M	$7.50M	(m)	$11.13M	(m)	-$2.69M
2020-06-30	$11.23M	$9.14M	(m)	$12.08M	(m)	$6.70M
2020-03-31	$4.66M	$4.12M	(m)	$6.78M	(m)	-$2.09M

Revenue and expense 6 month

Period end	Revenue	Research and development	Selling, general and administrative	Operating expenses	Income tax	Net income
2026-06-30	$12.36M	$92.65M	$26.18M	$132.66M	-$9.91M	-$98.59M
2025-06-30	$21.32M	$81.71M	$41.05M	$133.57M	-$8.98M	-$80.35M
2024-06-30	$17.28M	$80.21M	(m)	$165.63M	-$13.39M	-$77.54M
2023-06-30	$22.25M	$89.12M	(m)	$138.51M	-$15.51M	-$70.64M
2022-06-30	$362.50M	$53.05M	(m)	$145.94M	$62.14M	$161.79M
2021-06-30	$230.38M	$27.40M	(m)	$79.41M	$44.52M	$114.90M
2020-06-30	$15.88M	$13.26M	(m)	$18.86M	(m)	$4.61M

Revenue and expense 9 month

Period end	Revenue	Research and development	Operating expenses	Income tax	Net income
2025-09-30	$30.27M	$136.74M	$218.80M	-$20.63M	-$137.47M
2024-09-30	$23.78M	$121.18M	$265.79M	-$24.92M	-$128.65M
2023-09-30	$28.85M	$127.04M	$200.00M	-$26.18M	-$99.25M
2022-09-30	$463.88M	$79.63M	$209.59M	$82.10M	$188.41M
2021-09-30	$235.87M	$44.85M	$113.01M	$40.92M	$93.52M
2020-09-30	$25.25M	$20.76M	$29.99M	(m)	$1.92M

Revenue and expense 12 month

Period end	Revenue	Research and development	Operating expenses	Income tax	Net income
2025-12-31	$75.13M	$186.83M	$292.23M	-$31.18M	-$146.41M
2024-12-31	$28.83M	$167.26M	$343.60M	-$37.54M	-$162.86M
2023-12-31	$38.02M	$175.66M	$275.23M	-$27.63M	-$146.40M
2022-12-31	$485.42M	$107.88M	$268.91M	$80.58M	$158.52M
2021-12-31	$375.20M	$62.06M	$170.79M	$65.69M	$153.46M
2020-12-31	$233.16M	$29.39M	$77.12M	$38.91M	$118.92M
2019-12-31	$11.61M	$10.11M	$15.73M	(m)	-$2.21M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
ACADIA PHARMACEUTICALS INC (ACAD)	United States	$3.823B	11.45
Xenon Pharmaceuticals Inc. (XENE)		$3.684B	-14.27
Tango Therapeutics, Inc. (TNGX)	United States	$4.154B	-42.53
Organon & Co. (OGN)	United States	$3.603B	17.03
IDEAYA Biosciences, Inc. (IDYA)	United States	$3.540B	-20.52
Indivior Pharmaceuticals, Inc. (INDV)		$4.250B	14.09
Viking Therapeutics, Inc. (VKTX)	United States	$4.287B	-8.51
Amylyx Pharmaceuticals, Inc. (AMLX)	United States	$3.361B	-13.15
Enliven Therapeutics, Inc. (ELVN)	United States	$3.307B	-35.07
Arcutis Biotherapeutics, Inc. (ARQT)	United States	$3.303B	115.47